Christopher E. Nelson Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Assistant Professor

University of Arkansas

Last publication 2025 Last refreshed 2026-05-22

faculty

37 h-index 145 pubs 5,802 cited

Research Areas

Links

ORCID Google Scholar Lab Website Research Group

OverviewAI-generated summary

Christopher E. Nelson's research focuses on gene editing technologies, particularly CRISPR-Cas9, for therapeutic applications. His work investigates strategies for delivering these editing systems, with a recent emphasis on developing genome editing approaches for Duchenne muscular dystrophy through exon skipping. Nelson has published on the challenges and precision of RNA-guided DNA integration in muscle loci and has explored Cas9-specific immune responses in canine models of muscular dystrophy, which can impact the efficacy of local and systemic AAV CRISPR therapy.

His federally funded research includes projects exploring genomic and cellular determinants of gene therapy durability, funded by the NIH/National Institute of General Medical Sciences for $366,731, and non-viral delivery of CRISPR/Cas9 for targeted gene replacement, funded by the NIH/National Institute of Biomedical Imaging and Bioengineering for $241,722. He also contributes as a Co-PI on a National Science Foundation grant for Cell Derived Extracellular Matrix BIofiber Engineering ($427,760).

Nelson's scholarship metrics include an h-index of 37 and over 5,700 citations across 141 publications. He collaborates with researchers from the University of Arkansas at Little Rock and the University of Arkansas at Fayetteville, including Shilpi Agrawal, Made Harumi Padmaswari, Timothy J. Muldoon, and Abbey L. Stokes.

Metrics

h-index: 37
Publications: 145
Citations: 5,802

Selected Publications

Beyond the Cut: Long-read sequencing reveals complex genomic and transcriptomic changes in AAV-CRISPR therapy for Duchenne Muscular Dystrophy (2025)

DOI OpenAlex
Standardizing a Protocol for Streamlined Synthesis and Characterization of Lipid Nanoparticles to Enable Preclinical Research and Education (2025)

1 citation DOI OpenAlex
A dual-fluorescence assay for gene delivery vehicle screening in macrophages with an inflammation-inducible reporter construct (2025)

DOI OpenAlex
Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping (2025)

2 citations DOI OpenAlex
Resistance to Acetyl Coenzyme A Carboxylase (ACCase) Inhibitor in Lolium multiflorum: Effect of Multiple Target-Site Mutations (2024)

1 citation DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

2 citations DOI OpenAlex
Optimizing Recombinant Cas9 Expression: Insights from E. coli BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing (2024)

5 citations DOI OpenAlex
Precision and efficacy of RNA-guided DNA integration in high-expressing muscle loci (2024)

2 citations DOI OpenAlex
PINE-TREE enables efficient enrichment of prime-edited hPSCs (2023)

DOI OpenAlex
Delivery challenges for CRISPR—Cas9 genome editing for Duchenne muscular dystrophy (2023)

10 citations DOI OpenAlex
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies (2022)

6 citations DOI OpenAlex
Longitudinal examination of perfusion and angiogenesis markers in primary colorectal tumors shows distinct signatures for metronomic and maximum-tolerated dose strategies (2022)

1 citation DOI OpenAlex